Advertisement

Cancer Causes & Control

, 22:1553 | Cite as

Regular aspirin use and breast cancer risk in US Black Women

  • Jaclyn L. F. Bosco
  • Julie R. Palmer
  • Deborah A. Boggs
  • Elizabeth E. Hatch
  • Lynn RosenbergEmail author
Original paper

Abstract

Background

Epidemiologic studies have yet to provide consistent evidence to support a protective effect of aspirin and other non-steroidal anti-inflammatory drugs (NSAID) on the incidence of breast cancer.

Objective

We evaluated the relations of current use of aspirin, non-aspirin NSAIDs, and acetaminophen with breast cancer incidence in the Black Women’s Health Study.

Methods

Biennial follow-up of 59,000 study participants began in 1995. During 558,600 person-years of follow-up through 2007, 1,275 breast cancer cases were identified. Using Cox proportional hazards regression, we estimated incidence rate ratios (IRR) and 95% confidence intervals (CI) for associations of current and former use of aspirin, other NSAIDs, and acetaminophen with incident breast cancer.

Results

After adjustment for age, education, body mass index at age 18, physical activity, female hormone use, current smoking, and other NSAID use, the IRRs were 0.79 (95% CI = 0.66, 0.95) for current aspirin use and 0.68 (95% CI = 0.50, 0.92) for ≥5 years of aspirin use. Similar associations were observed for acetaminophen use.

Conclusions

Both aspirin and acetaminophen use were inversely associated with breast cancer incidence in the present study. Reasons for the association with acetaminophen use are unclear, given that acetaminophen has very weak anti-inflammatory effects.

Keywords

Aspirin NSAIDs Breast cancer Incidence Epidemiology 

Notes

Acknowledgments

This work was supported by the National Institutes of Health, National Cancer Institute grant R01 CA058420. Data on breast cancer pathology were obtained with institutional review board approval from several state cancer registries (AZ, CA, CO, CT, DE, DC, FL, GA, IL, IN, KY, LA, MD, MA, MI, NJ, NY, NC, OK, PA, SC, TN, TX, VA). The content of this paper is solely the responsibility of the authors and does not necessarily represent the views of the National Cancer Institute or the cancer registries. The authors gratefully acknowledge the contributions of the participants, investigators, and staff of the Black Women’s Health Study.

References

  1. 1.
    Rosenberg L, Louik C, Shapiro S (1998) Nonsteroidal antiinflammatory drug use and reduced risk of large bowel carcinoma. Cancer 82:2326–2333PubMedCrossRefGoogle Scholar
  2. 2.
    Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD, Shapiro S (1991) A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 83:355–358PubMedCrossRefGoogle Scholar
  3. 3.
    Thun MJ, Henley SJ, Patrono C (2002) Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94:252–266PubMedGoogle Scholar
  4. 4.
    Meier CR, Schmitz S, Jick H (2002) Association between acetaminophen or nonsteroidal antiinflammatory drugs and risk of developing ovarian, breast, or colon cancer. Pharmacotherapy 22:303–309PubMedCrossRefGoogle Scholar
  5. 5.
    Bosetti C, Gallus S, La Vecchia C (2006) Aspirin and cancer risk: an updated quantitative review to 2005. Cancer Causes Control 17:871–888PubMedCrossRefGoogle Scholar
  6. 6.
    DuBois RN (2004) Aspirin and breast cancer prevention. JAMA 291:2488–2489PubMedCrossRefGoogle Scholar
  7. 7.
    The Endogenous Hormones Breast Cancer Collaborative Group (2002) Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94:606–616Google Scholar
  8. 8.
    Hwang D, Scollard D, Byrne J, Levine E (1998) Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 90:455–460PubMedCrossRefGoogle Scholar
  9. 9.
    Diaz-Cruz ES, Shapiro CL, Brueggemeier RW (2005) Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells. J Clin Endocrinol Metab 90:2563–2570PubMedCrossRefGoogle Scholar
  10. 10.
    Howe LR, Lippman SM (2008) Modulation of breast cancer risk by nonsteroidal anti-inflammatory drugs. J Natl Cancer Inst 100:1420–1423PubMedCrossRefGoogle Scholar
  11. 11.
    Harris RE, Namboodiri KK, Stellman SD, Wynder EL (1995) Breast cancer and NSAID use: heterogeneity of effect in a case–control study. Prev Med 24:119–120PubMedCrossRefGoogle Scholar
  12. 12.
    Harris RE, Chlebowski RT, Jackson RD et al (2003) Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women’s Health Initiative. Cancer Res 63:6096–6101PubMedGoogle Scholar
  13. 13.
    Johnson TW, Anderson KE, Lazovich D, Folsom AR (2002) Association of aspirin and nonsteroidal anti-inflammatory drug use with breast cancer. Cancer Epidemiol Biomark Prev 11:1586–1591Google Scholar
  14. 14.
    Ready A, Velicer C, McTiernan A, White E (2008) NSAID use and breast cancer risk in the VITAL cohort. Breast Cancer Res Treat 109:533–543PubMedCrossRefGoogle Scholar
  15. 15.
    Jacobs EJ, Thun MJ, Connell CJ et al (2005) Aspirin and other nonsteroidal anti-inflammatory drugs and breast cancer incidence in a large US cohort. Cancer Epidemiol Biomark Prev 14:261–264CrossRefGoogle Scholar
  16. 16.
    Egan KM, Stampfer MJ, Giovannucci E, Rosner BA, Colditz GA (1996) Prospective study of regular aspirin use and the risk of breast cancer. J Natl Cancer Inst 88:988–993PubMedCrossRefGoogle Scholar
  17. 17.
    Eliassen AH, Chen WY, Spiegelman D, Willett WC, Hunter DJ, Hankinson SE (2009) Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and risk of breast cancer among premenopausal women in the Nurses’ Health Study II. Arch Intern Med 169:115–121PubMedCrossRefGoogle Scholar
  18. 18.
    Marshall SF, Bernstein L, Anton-Culver H et al (2005) Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status. J Natl Cancer Inst 97:805–812PubMedCrossRefGoogle Scholar
  19. 19.
    Gill JK, Maskarinec G, Wilkens LR, Pike MC, Henderson BE, Kolonel LN (2007) Nonsteroidal antiinflammatory drugs and breast cancer risk: the multiethnic cohort. Am J Epidemiol 166:1150–1158PubMedCrossRefGoogle Scholar
  20. 20.
    Gierach G, Lacey J, Schatzkin A et al (2008) Nonsteroidal anti-inflammatory drugs and breast cancer risk in the National Institutes of Health-AARP Diet and Health Study. Breast Cancer Res 10:R38PubMedCrossRefGoogle Scholar
  21. 21.
    Cook NR, Lee IM, Gaziano JM et al (2005) Low-dose aspirin in the primary prevention of cancer: the Women’s Health Study: a randomized controlled trial. JAMA 294:47–55PubMedCrossRefGoogle Scholar
  22. 22.
    Zhang SM, Cook NR, Manson JE, Lee I-M, Buring JE (2008) Low-dose aspirin and breast cancer risk: results by tumour characteristics from a randomised trial. Br J Cancer 98:989–991PubMedCrossRefGoogle Scholar
  23. 23.
    Moorman P, Grubber J, Millikan R, Newman B (2003) Association between non-steroidal anti-inflammatory drugs (NSAIDs) and invasive breast cancer and carcinoma in situ of the breast. Cancer Causes Control 14:915–922PubMedCrossRefGoogle Scholar
  24. 24.
    Palmer JR, Rao SR, Adams-Campbell LL, Rosenberg L (2001) Height and breast cancer risk: results from the Black Women’s Health Study (United States). Cancer Causes Control 12:343–348PubMedCrossRefGoogle Scholar
  25. 25.
    Kelley KE, Kelley TP, Kaufman DW, Mitchell AA (2003) The Slone Drug Dictionary: a research driven pharmacoepidemiology tool. Pharmacoepidemiol Drug Saf 12(S1):S168–S198Google Scholar
  26. 26.
    Stephenson GD, Rose DP (2003) Breast cancer and obesity: an update. Nutr Cancer 45:1–16PubMedCrossRefGoogle Scholar
  27. 27.
    Monninkhof EM, Elias SG, Vlems FA et al (2007) Physical activity and breast cancer: a systematic review. Epidemiol 18:137–157CrossRefGoogle Scholar
  28. 28.
    Band PR, Le ND, Fang R, Deschamps M (2002) Carcinogenic and endocrine disrupting effects of cigarette smoke and risk of breast cancer. Lancet 360:1044–1049PubMedCrossRefGoogle Scholar
  29. 29.
    Boffetta P, Hashibe M (2006) Alcohol and cancer. Lancet Oncol 7:149–156PubMedCrossRefGoogle Scholar
  30. 30.
    Kelsey JL (1993) Breast cancer epidemiology: summary and future directions. Epidemiol Rev 15:256–263PubMedGoogle Scholar
  31. 31.
    Kelsey JL, Gammon MD, John EM (1993) Reproductive factors and breast cancer. Epidemiol Rev 15:36–47PubMedGoogle Scholar
  32. 32.
    Kelsey JL, Horn-Ross PL (1993) Breast cancer: magnitude of the problem and descriptive epidemiology. Epidemiol Rev 15:7–16PubMedGoogle Scholar
  33. 33.
    Cox DR (1972) Regression models and life-tables. J R Stat Soc Ser B Methodol 34:187–220Google Scholar
  34. 34.
    Therneau TM, Grambsch PM (2000) Modeling survival data: extending the Cox model. Springer, New YorkGoogle Scholar
  35. 35.
    Coogan PF, Rao SR, Rosenberg L et al (1999) The relationship of nonsteroidal anti-inflammatory drug use to the risk of breast cancer. Prev Med 29:72–76PubMedCrossRefGoogle Scholar
  36. 36.
    Brasky TM, Bonner MR, Moysich KB et al (2010) Non-steroidal anti-inflammatory drug (NSAID) use and breast cancer risk in the Western New York Exposures and Breast Cancer (WEB) Study. Cancer Causes Control 21:1503–1512PubMedCrossRefGoogle Scholar
  37. 37.
    Pedersen ATn, Ottesen B (2003) Issues to debate on the Women’s Health Initiative (WHI) study. Epidemiology or randomized clinical trial—time out for hormone replacement therapy studies? Hum Reprod 18:2241–2244PubMedCrossRefGoogle Scholar
  38. 38.
    Garcia Rodriguez LA, Gonzalez-Perez A (2004) Risk of breast cancer among users of aspirin and other anti-inflammatory drugs. Br J Cancer 91:525–529PubMedCrossRefGoogle Scholar
  39. 39.
    Cronin-Fenton D, Pedersen L, Lash T, Friis S, Baron J, Sørensen HT (2010) Prescriptions for selective cyclooxygenase-2 inhibitors, non-selective non-steroidal anti-inflammatory drugs, and risk of breast cancer in a population-based case–control study. Breast Cancer Res 12:R15PubMedCrossRefGoogle Scholar
  40. 40.
    Harris R, Beebe-Donk J, Alshafie G (2006) Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer 6:27PubMedCrossRefGoogle Scholar
  41. 41.
    Rahme E, Ghosn J, Dasgupta K, Rajan R, Hudson M (2005) Association between frequent use of nonsteroidal anti-inflammatory drugs and breast cancer. BMC Cancer 5:159PubMedCrossRefGoogle Scholar
  42. 42.
    Terry MB, Gammon MD, Zhang FF et al (2004) Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA 291:2433–2440PubMedCrossRefGoogle Scholar
  43. 43.
    Gallicchio L, Visvanathan K, Burke A, Hoffman SC, Helzlsouer KJ (2007) Nonsteroidal anti-inflammatory drugs and the risk of developing breast cancer in a population-based prospective cohort study in Washington County, MD. Int J Cancer 121:211–215PubMedCrossRefGoogle Scholar
  44. 44.
    Friis S, Thomassen L, Sørensen HT et al (2008) Nonsteroidal anti-inflammatory drug use and breast cancer risk: a Danish cohort study. Euro J Cancer Prev 17:88–96CrossRefGoogle Scholar
  45. 45.
    Gates MA, Tworoger SS, Eliassen AH, Missmer SA, Hankinson SE (2010) Analgesic use and sex steroid hormone concentrations in postmenopausal women. Cancer Epidemiol Biomark Prev 19:1033–1041CrossRefGoogle Scholar
  46. 46.
    Graham GG, Scott KF (2005) Mechanism of action of paracetamol. Am J Therap 12:46–55CrossRefGoogle Scholar
  47. 47.
    Anderson BJ (2008) Paracetamol (acetaminophen): mechanisms of action. Paediatr Anaesth 18:915–921PubMedCrossRefGoogle Scholar
  48. 48.
    Aronoff DM, Oates JA, Boutaud O (2006) New insights into the mechanism of action of acetaminophen: its clinical pharmacologic characteristics reflect its inhibition of the two prostaglandin H2 synthases. Clin Pharmacol Therapeutics 79:9–19CrossRefGoogle Scholar
  49. 49.
    Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr (1993) Aspirin use and risk of fatal cancer. Cancer Res 53:1322–1327PubMedGoogle Scholar
  50. 50.
    Garcia Rodriguez LA, Gonzalez-Perez A (2004) Risk of breast cancer among users of aspirin and other anti-inflammatory drugs (NSAIDs) and invasive breast cancer and carcinoma in situ of the breast. Cancer Causes Control 91:525–529Google Scholar
  51. 51.
    Schreinemachers DM, Everson RB (1994) Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiol 5:135–146CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2011

Authors and Affiliations

  • Jaclyn L. F. Bosco
    • 1
    • 2
  • Julie R. Palmer
    • 3
  • Deborah A. Boggs
    • 3
  • Elizabeth E. Hatch
    • 2
  • Lynn Rosenberg
    • 3
    Email author
  1. 1.Section of Geriatrics, Department of MedicineBoston University School of MedicineBostonUSA
  2. 2.Department of EpidemiologyBoston University School of Public HealthBostonUSA
  3. 3.Slone Epidemiology Center at Boston UniversityBostonUSA

Personalised recommendations